Iron-overload disorders are common and could lead to significant morbidity and mortality worldwide. Due to limited treatment options, there is a great need to develop novel strategies to remove the excess body iron. To discover potential epigenetic modulator in hepcidin upregulation and subsequently decreasing iron burden, we performed an epigenetic screen. The in vivo effects of the identified compounds were further tested in iron-overload mouse models, including Hfe−/−, Hjv−/−, and hepatocyte-specific Smad4 knockout (Smad4fl/fl;Alb-Cre+) mice.
Results:
Entinostat (MS-275), the clinical used histone deacetylase 1 (HDAC1) inhibitor, was identified the most potent hepcidin agonist. Consistently, Hdac1-deficient mice also presented higher hepcidin levels than wild-type controls. Notably, the long-term treatment with entinostat in Hfe−/− mice significantly alleviated iron overload through upregulating hepcidin transcription. In contrast, entinostat showed no effect on hepcidin expression and iron levels in Smad4fl/fl;Alb-Cre+ mice. Further mechanistic studies revealed that HDAC1 suppressed expression of hepcidin through interacting with SMAD4 rather than deacetylation of SMAD4 or histone-H3 on the hepcidin promoter.
Innovation:
The findings uncovered HDAC1 as a novel hepcidin suppressor through complexing with SMAD4 but not deacetylation of either histone 3 or SMAD4. In addition, our study suggested a novel implication of entinostat in treating iron-overload disorders.
Conclusions:
Based on our results, we conclude that entinostat strongly activated hepcidin in vivo and in vitro. HDAC1 could serve as a novel hepcidin suppressor by binding to SMAD4, effect of which is independent of BMP/SMAD1/5/8 signaling. Antioxid. Redox Signal. 28, 1224–1237.
Get full access to this article
View all access options for this article.
References
1.
AlkhateebAA, BuckettPD, GardeckAM, KimJ, ByrneSL, FraenkelPG, and Wessling-ResnickM. The small molecule ferristatin II induces hepatic hepcidin expression in vivo and in vitro. Am J Physiol Gastrointest Liver Physiol, 308: G1019–G1026, 2015.
2.
AshbyDR, GaleDP, BusbridgeM, MurphyKG, DuncanND, CairnsTD, TaubeDH, BloomSR, TamFW, ChapmanR, MaxwellPH, and ChoiP. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica, 95: 505–508, 2010.
3.
AshizawaT, MiyataH, IshiiH, OshitaC, MatsunoK, MasudaY, FuruyaT, OkawaraT, OtsukaM, OgoN, AsaiA, and AkiyamaY. Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation. Int J Oncol, 38: 1245–1252, 2011.
4.
Besson-FournierC, LatourC, KautzL, BertrandJ, GanzT, RothMP, and CoppinH. Induction of activin B by inflammatory stimuli up-regulates expression of the iron-regulatory peptide hepcidin through Smad1/5/8 signaling. Blood, 120: 431–439, 2012.
5.
CasuC, OikonomidouPR, ChenH, NandiV, GinzburgY, PrasadP, FlemingRE, ShahYM, ValoreEV, NemethE, GanzT, MacDonaldB, and RivellaS. Minihepcidin peptides as disease modifiers in mice affected by beta-thalassemia and polycythemia vera. Blood, 128: 265–276, 2016.
6.
CrosbyWH. Dietary iron overload. N Engl J Med, 326: 1705; author reply 1705–1706, 1992.
7.
DalgardCL, Van QuillKR, and O'BrienJM. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma. Clin Cancer Res, 14: 3113–3123, 2008.
8.
De DomenicoI, WardDM, and KaplanJ. Hepcidin regulation: ironing out the details. J Clin Invest, 117: 1755–1758, 2007.
9.
De FeliceC, Della RagioneF, SignoriniC, LeonciniS, PecorelliA, CiccoliL, ScalabriF, MarracinoF, MadonnaM, BelmonteG, RicceriL, De FilippisB, LaviolaG, ValacchiG, DurandT, GalanoJM, OgerC, GuyA, Bultel-PonceV, GuyJ, FilosaS, HayekJ, and D'EspositoM. Oxidative brain damage in Mecp2-mutant murine models of Rett syndrome. Neurobiol Dis, 68: 66–77, 2014.
10.
DownesM, OrdentlichP, KaoHY, AlvarezJG, and EvansRM. Identification of a nuclear domain with deacetylase activity. Proc Natl Acad Sci U S A, 97: 10330–10335, 2000.
11.
FinbergKE, WhittleseyRL, and AndrewsNC. Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice. Blood, 117: 4590–4599, 2011.
12.
GammellaE, DiazV, RecalcatiS, BurattiP, SamajaM, DeyS, NoguchiCT, GassmannM, and CairoG. Erythropoietin's inhibiting impact on hepcidin expression occurs indirectly. Am J Physiol Regul Integr Comp Physiol, 308: R330–R335, 2015.
13.
GanzT. Hepcidin—a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Haematol, 18: 171–182, 2005.
14.
GanzT. Hepcidin and iron regulation, 10 years later. Blood, 117: 4425–4433, 2011.
15.
GaunV, PatchenB, VolovetzJ, ZhenAW, AndreevA, PollastriMP, and FraenkelPG. A chemical screen identifies small molecules that regulate hepcidin expression. Blood Cells Mol Dis, 53: 231–240, 2014.
16.
GuanY, AnP, ZhangZ, ZhangF, YuY, WuQ, ShiY, GuoX, TaoY, and WangF. Screening identifies the Chinese medicinal plant Caulis Spatholobi as an effective HAMP expression inhibitor. J Nutr, 143: 1061–1066, 2013.
17.
HaqueS, ChandraB, GerberMA, and LokAS. Iron overload in patients with chronic hepatitis C: a clinicopathologic study. Hum Pathol, 27: 1277–1281, 1996.
18.
HassigCA, TongJK, FleischerTC, OwaT, GrablePG, AyerDE, and SchreiberSL. A role for histone deacetylase activity in HDAC1-mediated transcriptional repression. Proc Natl Acad Sci U S A, 95: 3519–3524, 1998.
HuangFW, PinkusJL, PinkusGS, FlemingMD, and AndrewsNC. A mouse model of juvenile hemochromatosis. J Clin Invest, 115: 2187–2191, 2005.
21.
JaboinJ, WildJ, HamidiH, KhannaC, KimCJ, RobeyR, BatesSE, and ThieleCJ. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res, 62: 6108–6115, 2002.
22.
KangJS, AllistonT, DelstonR, and DerynckR. Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3. EMBO J, 24: 2543–2555, 2005.
23.
KautzL, JungG, ValoreEV, RivellaS, NemethE, and GanzT. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet, 46: 678–684, 2014.
24.
LahertyCD, BillinAN, LavinskyRM, YochumGS, BushAC, SunJM, MullenTM, DavieJR, RoseDW, GlassCK, RosenfeldMG, AyerDE, and EisenmanRN. SAP30, a component of the mSin3 corepressor complex involved in N-CoR-mediated repression by specific transcription factors. Mol Cell, 2: 33–42, 1998.
25.
MahendrarajahN, PaulusR, and KramerOH. Histone deacetylase inhibitors induce proteolysis of activated CDC42-associated kinase-1 in leukemic cells. J Cancer Res Clin Oncol, 142: 2263–2273, 2016.
26.
MiuraK, TauraK, KodamaY, SchnablB, and BrennerDA. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology, 48: 1420–1429, 2008.
27.
Mleczko-SaneckaK, da SilvaAR, CallD, NevesJ, SchmeerN, DammG, SeehoferD, and MuckenthalerMU. Imatinib and spironolactone suppress hepcidin expression. Haematologica, 102: 1173–1184, 2017.
28.
MuM, WuA, AnP, DuX, WuQ, ShenX, and WangF. Black soyabean seed coat extract regulates iron metabolism by inhibiting the expression of hepcidin. Br J Nutr, 111: 1181–1189, 2014.
29.
NagyL, KaoHY, ChakravartiD, LinRJ, HassigCA, AyerDE, SchreiberSL, and EvansRM. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell, 89: 373–380, 1997.
30.
NemethE, RoettoA, GarozzoG, GanzT, and CamaschellaC. Hepcidin is decreased in TFR2 hemochromatosis. Blood, 105: 1803–1806, 2005.
31.
NicolasG, ViatteL, LouDQ, BennounM, BeaumontC, KahnA, AndrewsNC, and VaulontS. Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat Genet, 34: 97–101, 2003.
32.
PandurE, SiposK, GramaL, NagyJ, PoorVS, SetaloG, MisetaA, and FeketeZ. Prohepcidin binds to the HAMP promoter and autoregulates its own expression. Biochem J, 451: 301–311, 2013.
33.
PhatakP, BrissotP, WursterM, AdamsPC, BonkovskyHL, GrossJ, MalfertheinerP, McLarenGD, NiederauC, PipernoA, PowellLW, RussoMW, StoelzelU, StremmelW, GriffelL, LynchN, ZhangY, and PietrangeloA. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology, 52: 1671–1779, 2010.
34.
PoliM, GirelliD, CampostriniN, MaccarinelliF, FinazziD, LuscietiS, NaiA, and ArosioP. Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo. Blood, 117: 997–1004, 2011.
35.
RameyG, DescheminJC, and VaulontS. Cross-talk between the mitogen activated protein kinase and bone morphogenetic protein/hemojuvelin pathways is required for the induction of hepcidin by holotransferrin in primary mouse hepatocytes. Haematologica, 94: 765–772, 2009.
36.
RamosE, RuchalaP, GoodnoughJB, KautzL, PrezaGC, NemethE, and GanzT. Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis. Blood, 120: 3829–3836, 2012.
37.
RoettoA, PapanikolaouG, PolitouM, AlbertiF, GirelliD, ChristakisJ, LoukopoulosD, and CamaschellaC. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet, 33: 21–22, 2003.
38.
RuizR, RaezLE, and RolfoC. Entinostat (SNDX-275) for the treatment of non-small cell lung cancer. Expert Opin Investig Drugs, 24: 1101–1109, 2015.
39.
SaitoA, YamashitaT, MarikoY, NosakaY, TsuchiyaK, AndoT, SuzukiT, TsuruoT, and NakanishiO. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A, 96: 4592–4597, 1999.
40.
SchmidtPJ, ToudjarskaI, SendamaraiAK, RacieT, MilsteinS, BettencourtBR, HettingerJ, BumcrotD, and FlemingMD. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine beta-thalassemia intermedia. Blood, 121: 1200–1208, 2013.
41.
TangJ, YanY, ZhaoTC, BaylissG, YanH, and ZhuangS. Class I histone deacetylase activity is required for proliferation of renal epithelial cells. Am J Physiol Renal Physiol, 305: F244–F254, 2013.
42.
TangYN, DingWQ, GuoXJ, YuanXW, WangDM, and SongJG. Epigenetic regulation of Smad2 and Smad3 by profilin-2 promotes lung cancer growth and metastasis. Nat Commun, 6: 8230, 2015.
43.
TaoY, WuQ, GuoX, ZhangZ, ShenY, and WangF. MBD5 regulates iron metabolism via methylation-independent genomic targeting of Fth1 through KAT2A in mice. Br J Haematol, 166: 279–291, 2014.
44.
TaplickJ, KurtevV, KrobothK, PoschM, LechnerT, and SeiserC. Homo-oligomerisation and nuclear localisation of mouse histone deacetylase 1. J Mol Biol, 308: 27–38, 2001.
45.
TruksaJ, LeeP, and BeutlerE. Two BMP responsive elements, STAT, and bZIP/HNF4/COUP motifs of the hepcidin promoter are critical for BMP, SMAD1, and HJV responsiveness. Blood, 113: 688–695, 2009.
46.
VerdinE and OttM. 50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond. Nat Rev Mol Cell Biol, 16: 258–264, 2015.
47.
ViatteL, NicolasG, LouDQ, BennounM, Lesbordes-BrionJC, Canonne-HergauxF, SchonigK, BujardH, KahnA, AndrewsNC, and VaulontS. Chronic hepcidin induction causes hyposideremia and alters the pattern of cellular iron accumulation in hemochromatotic mice. Blood, 107: 2952–2958, 2006.
48.
WangRH, LiC, XuX, ZhengY, XiaoC, ZerfasP, CoopermanS, EckhausM, RouaultT, MishraL, and DengCX. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab, 2: 399–409, 2005.
49.
WiltingRH, YanoverE, HeidemanMR, JacobsH, HornerJ, van der TorreJ, DePinhoRA, and DannenbergJH. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J, 29: 2586–2597, 2010.
50.
WuQ, WangH, AnP, TaoY, DengJ, ZhangZ, ShenY, ChenC, MinJ, and WangF. HJV and HFE play distinct roles in regulating hepcidin. Antioxid Redox Signal, 22: 1325–1336, 2015.
51.
YangX, ParkSH, ChangHC, ShapiroJS, VassilopoulosA, SawickiKT, ChenC, ShangM, BurridgePW, EptingCL, WilsbacherLD, JenkitkasemwongS, KnutsonM, GiusD, and ArdehaliH. Sirtuin 2 regulates cellular iron homeostasis via deacetylation of transcription factor NRF2. J Clin Invest, 127: 1505–1516, 2017.
52.
ZhangQ, SongY, ChenW, WangX, MiaoZ, CaoL, LiF, and WangG. By recruiting HDAC1, MORC2 suppresses p21 Waf1/Cip1 in gastric cancer. Oncotarget, 6: 16461–16470, 2015.
53.
ZhangY, SunZW, IratniR, Erdjument-BromageH, TempstP, HampseyM, and ReinbergD. SAP30, a novel protein conserved between human and yeast, is a component of a histone deacetylase complex. Mol Cell, 1: 1021–1031, 1998.
54.
ZhangZ, ZhangF, AnP, GuoX, ShenY, TaoY, WuQ, ZhangY, YuY, NingB, NieG, KnutsonMD, AndersonGJ, and WangF. Ferroportin1 deficiency in mouse macrophages impairs iron homeostasis and inflammatory responses. Blood, 118: 1912–1922, 2011.
55.
ZhenAW, NguyenNH, GibertY, MotolaS, BuckettP, Wessling-ResnickM, FraenkelE, and FraenkelPG. The small molecule, genistein, increases hepcidin expression in human hepatocytes. Hepatology, 58: 1315–1325, 2013.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
